Advertisement

Topics

FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat

11:47 EST 20 Dec 2018 | Investing News Network

FibroGen (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in the three global pivotal Phase 3 trials conducted by FibroGen: ANDES in non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients, HIMALAYAS in incident … Continued

The post FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat appeared first on Investing News Network.

Original Article: FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat

NEXT ARTICLE

More From BioPortfolio on "FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...